Sun Pharmaceutical Industries Limited Announced That It Has Received Final Approval From Us Fda For Its Abbreviated New Drug Application (Anda) For Generic Mesalamine Extended Release Capsules, 500 Mg. The Generic Product Approval Is Based On Pentasa Extended Release Capsules, 500Mg As A Reference Product. As Per March 2022 Iqvia Health Data, Pentasa Extended Release Capsules, 500Mg Had Annualized Sales Of Approximately Us$ 213 Million In Usa. Sun Pharma Is The World'S Fourth Largest Specialty Generic Pharmaceutical Company And India'S Top Pharmaceutical Company.
